The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.

A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.

Single, double and even triple-payload ADCs will be presented at the meeting.

Talapro-3 could help move Talzenna into earlier prostate cancer.

First human data on MK-2010 are imminent.

The company’s TRPV1 antagonist looks doomed.

The Chinese company will start the first of four pivotal trials of its PD-L1 ADC in April. 

The company admits defeat with zelenectide.

But this comes in second-line breast cancer, a use the group isn’t pursuing.

Varseta-M efficacy wanes, but more than justifies a pivotal trial.